source
- Regeneron wins FDA approval for Pasatru, targeting rare bone disease FOPThe U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals' drug Pasatru for the treatment of fibrodysplasia ossificans progressiva (FOP), a very rare condition in which muscle an…
- PhRMA weighs former Republican lawmakers and Trump administration officials for CEO rolePhRMA, the pharma lobbying group, has been searching for a new chief executive for over four months. The search has focused on candidates with Republican backgrounds, including former members of C…